Krystal Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 157.62K shares, a 454.79% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 145.13K shares, a 747.57% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 207.85K shares, a 466.29% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 56.94K shares, a 18.31% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 310.32K shares, a 40.99% decline from fiscal 2024.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 525.86K shares, a 30.14% decline from fiscal 2023.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 752.75K shares, a 442.11% increase from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 138.85K shares, a 155.91% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 157.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 567.54K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 145.13K shares 10-Q · filed 2026-05-04 | 438.33K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | 207.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 310.32K shares 10-K · filed 2026-02-17 |
| 2025-09-30 | 56.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 139.17K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | 28.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 130.36K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | 17.12K shares 10-Q · filed 2026-05-04 | 283.40K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | 36.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 525.86K shares 10-K · filed 2026-02-17 |
| 2024-09-30 | 48.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 531.17K shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | 181.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 702.78K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | 259.58K shares 10-Q · filed 2025-05-06 | 970.31K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | 42.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | 752.75K shares 10-K · filed 2025-02-19 |
| 2023-09-30 | 219.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | 764.81K shares derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | 448.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 590.45K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | 42.02K shares 10-Q · filed 2024-05-06 | 179.40K shares derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | 54.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 138.85K shares 10-K · filed 2024-02-26 |
| 2022-09-30 | 45.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 89.31K shares derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-06-30 | 37.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 76.78K shares derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-03-31 | 1.48K shares 10-Q · filed 2022-05-09 | 39.94K shares derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-12-31 | 4.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 54.26K shares 10-K · filed 2023-02-27 |
| 2021-09-30 | 32.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 57.08K shares derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-06-30 | 1.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 67.03K shares derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-03-31 | 15.80K shares 10-Q · filed 2021-05-10 | 82.95K shares derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-12-31 | 7.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 84.28K shares 10-K · filed 2022-02-28 |
| 2020-09-30 | 42.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 124.23K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | 17.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 90.04K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | 17.13K shares 10-Q · filed 2020-05-04 | 74.55K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | 47.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 72.07K shares 10-K · filed 2021-03-01 |
| 2019-09-30 | 8.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | 24.78K shares derived: sum of 4 quarters · filed 2020-03-10 |
| 2019-06-30 | 1.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | 16.15K shares derived: sum of 4 quarters · filed 2020-03-10 |
| 2019-03-31 | 14.65K shares 10-Q · filed 2019-05-07 | 16.53K shares derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | 4.24K shares 10-K · filed 2020-03-10 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 4.24K shares derived: sum of 4 quarters · filed 2018-11-05 |
| 2018-06-30 | 1.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | |
| 2018-03-31 | 2.37K shares 10-Q · filed 2018-05-07 | |
| 2017-12-31 | 0.00 shares derived: 10-Q 12 month − 10-Q 9 month · filed 2018-11-05 | 0.00 shares 10-Q · filed 2018-11-05 |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |